Calciumfolinat

DRUG2 trials

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Conditions

Gastric CancerGastroesophageal Junction AdenocarcinomaGastroesophageal Junction CancerStomach Cancer

Phase 2

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

CompletedNCT02661971

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestGastroesophageal Junction Cancer, Stomach Cancer

Start: 2016-06-30End: 2022-06-20Updated: 2022-07-11

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Active, not recruitingNCT03421288

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestGastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2018-09-14End: 2027-12-31Updated: 2025-07-25

Related Papers

A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.

Journal of Clinical Oncology2024-06-011 citations

Locally advanced mismatch repair‐deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring

CA A Cancer Journal for Clinicians2023-10-172 citations

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.

2023-09-18110 citations

A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.

Journal of Clinical Oncology2023-06-0113 citations

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Journal of Clinical Oncology2022-06-0194 citations

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

Journal of Clinical Oncology2022-06-014 citations

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

Journal of Clinical Oncology2020-05-2030 citations

Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.

Journal of Clinical Oncology2020-05-2013 citations

Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.

Journal of Clinical Oncology2020-02-016 citations

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Journal of Clinical Oncology2019-05-2023 citations

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

2018-09-10105 citations